Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Second phase III trial of AVP-786 for agitation in Alzheimer's dementia misses endpoints

Sep. 30, 2019

Enrollment ongoing in phase II study of JNJ-61393215 for the treatment of depression

Sep. 30, 2019

Phase II study of ganaxolone in refractory status epilepticus meets primary endpoint

Sep. 27, 2019

Clinical phase IIa data on RNS-60 for multiple sclerosis presented

Sep. 27, 2019

Sunshine Lake Pharma patents MAO-B inhibitors

Sep. 26, 2019

SARM1: a new therapeutic target for MS and other neurodegenerative disorders

Sep. 26, 2019

Promising interim data presented from phase I/IIa study of AstroRx cell therapy in patients with ALS

Sep. 26, 2019

Sympathetic nervous system can protect from autoimmunity

Sep. 26, 2019

Reaction Biology prepares and tests HDAC inhibitors

Sep. 25, 2019

Ovid announces positive initial data from ongoing ENDYMION extension trial of soticlestat

Sep. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
In vivo click ADCs could address tumor heterogeneity
BioWorld
Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...
Other news to note for July 20, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cellution, Dimerix, Elutia, IPG, Jasper, Kira, Lumibird, Medtronic,...